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Introduction 
Driving under the influence of alcohol on Irish roads is 
well publicised. In 1999, of the 8,476 sampler submitted 
by the Gardai to the Medical Bureau of Road safety for 
alcohol analysis, 92 per cent were over the legal alcohol 
limit. 
 Driving under the influence of drugs has been 
illegal under statute in Ireland since the 1961 Road 
Traffic Act. An initial survey was carried out in the 
Medical Bureau of Road Safety between I987 and 1991 
to investigate driving under the influence of drugs on 
Irish roads One thousand urine samples under the legal 
alcohol limit und 1,000 random samples were tested for 
the presence of cannabis, benzodiazepines and opiates 
Screening results (using an EMIT system) showed 14.6 
per cent of samples under the legal alcohol limit and 66 
per cent of the random samples to contain drugs. 
 More recently, the European Monitoring Centre 
for Drugs and Drug Addiction (HMCDDA) has earned 
out extensive research into the role that drug use plays 
in impaired driving and traffic accidents in EU Member 
States. It is also responsible for identifying trends in 
driving under the influence of drugs across Europe. 
 To determine current trends in driving under the 
influence of drugs in Ireland, a survey earned out during 
2000 and 2001 will investigate the presence of 
amphetamines benzodtazepines, cannabis, cocaine, 
opiates and methadone in blood and urine samples taken 
by the Gardai under the Road Traffic Act 1994. As with 
the previous Study, 1,000 of these samples will be 
randomly selected and 1,000 will he under the legal 
alcohol limit for driving. The results of a preliminary 
study of 338 samples, showing current trends, will be 
presented here. 
 
 
 Microplate Enzyme Immunoassay kits are used 
to screen for the following drugs: 
Kit Analyte 
Amphetamine: Amphetamine, 
Methylenedioxyamphetamine (MDA) 
Methamphetamine: Methylenedioxymethamphetamine 
(MDMA) 
Benzediazepines: Diazepam, Flunitrazepam, 
Flurazepam, Nitrazepam, 
Nordiazepma, Temazepam 
Cannabis: 11-nor-delta-delta-9-carboxy- 
Tetrahydrocannabinol 
Cocaine: Cocaine, Benzoylecgonine, 
Ecgonine Methyl Ester 
Opiates: Codeine, Dihydrocodeine, Morphine, 
6-MAM 
Methadone: Methadone, EDDP 
Materials 
Cozart 96 well Blood/Serum EIA kits for Amphetamine, 
Methamphetamine, Benzodiazepines, Cannabinoids, Cocaine. 
Opiates und Methadone (Cozart Bioscience Ltd., UK). 
High and Low Blood Controls for proficiency testing (Cozart 
Bioscience Ltd.) 
Gilson 25µl Microman pipette (AGO Scientific Ltd.). 
Finnpipette Multistepper (Brownes) 
Hamilton Microlab 500 series diluter. 
MRW automatic plate washer (Shaw Scientific Ltd.). 
Dynex MRX11 Plate Render (Shaw Scientific Ltd.). 
Revelation Software. 
Procedure (Fig. 1) 
− Sample preparation consisted of a one-in-five 
dilution with water. Blanks and controls were 
also diluted in the same way. 
− Control blood samples were tested with each kit. 
Two levels of control were used: a low control 
with a concentration at the kit cut-off level and a 
high control. Controls had been spiked with the 
calibrator drug for the seven kits. 
− A standard curve, blank blood, blank urine and 
high and low-level controls were tested with 
each batch of samples. 
− The procedure provided with each kit was 
followed, and absorbance was read at 450 nm. 
− A 10 per cent coefficient of variation was 
allowed for standard solutions and 20 per cent 
for controls and samples 
RESULTS AND DISCUSSION 
All samples submitted to the Medical Bureau of Road 
Safety between July 1, 1999 and December 31, 1999 
that were under the legal limit for alcohol were tested 
for the 
 
presence of drugs. In total, 338 samples were tested, 57 
per cent of which were blood and 43 per cent urine. As 
it is the driver’s choice which sample to give, the testing 
system had to allow for testing of both blood and urine. 
The traditionally used EMIT system was developed for 
urine testing and therefore lengthy extraction procedures 
are necessary for blood analysis. The Cozart Enzyme 
Immunoassay system is calibrated using serum 
standards hut is readily adaptable for the analysis of 
urine in addition to blood, as drug concentration levels 
in urine arc much higher than in blood. A simple 
dilution with water is all the preparation that is 
necessary. 
 Thirty-seven per cent of the samples tested were 
positive for drugs, the classification of which is 
represented in Figure 2. Cannabis was found most 
frequently followed by benzodiazepines. Cocaine was 
the least common, occurring in only four per cent of 
samples. 
 The occurrence of polydrug use was frequent. 
Results shown in Figure 3 indicate that 45 per cent of 
samples tested contained two or more types of drugs, 
with three per cent of samples containing five types of 
drugs. 
Drugs and Alcohol 
The interaction between alcohol and drugs can greatly 
enhance the impairment of a driver, e.g. a combination 
of alcohol and cocaine forms Cocaethylene, which itself 
is pharmacologically active. For this reason it is 
important to identify trends in driving under the 
influence of a combination of drugs and alcohol. 
Analysis of the results to dale indicates that in the 
majority of samples where drugs are detected some 
level of 
 
 
alcohol is present also. Although all the samples tested 
for drugs were under the legal alcohol limit, only 22 per 
cent of the samples contained no alcohol at all. In the 
majority of these samples, the incidence of polydrug use 
was very high. The frequency of the combination of 
alcohol and drugs are in Table 1. 
Table 1: Combination of Drugs and Alcohol. 
Analytical Alcohol Level 
Percentage of 
Positive Samples 
0 – 10 mg/100ml blood 
0 – 10 mg/100ml urine 22% 
11 – 69 mg/100ml blood; 
11 – 99 mg/100ml urine 48% 
70 – 86 mg/100ml blood; I 
100 – 114 mg/100ml urine 30% 
Confirmatory Analysis 
The results presented so tar are based on screening tests 
that are used to identify- particular classes of drugs 
present in a sample. Immunoassay screens often read 
higher concentrations due to the kit cross reacting with a 
variety of metabolites in a sample. Confirmatory 
analysis detects specific analyses. .Screening results are 
also affected by the sample matrix, which is reduced m 
confirmatory analysis through extensive sample clean-
up. It also eliminates false positives, in addition to 
aiding the interpretation of results 
 For these reasons, confirmatory analysis is 
necessary to identity and quantify drugs present in 
samples. All confirmatory analysis was carried out by 
the Toxicology Section of the State Laboratory. 
Confirmation of amphetamines, cannabis, cocaine and 
opiates was by Gas Chromaiography with Mass 
Spcetrometric detection (GC/MS) using a Finnegan 
Magnum ion-trap instrument run in Electron lonisation 
mode. 
 Benzodiazepine and methadone confirmation 
was carried out by Dual-Column Gas Chromatography 
with Nitrogen-Phosphorus Detector. 
Confirmatory Analysis - Results to Date 
Amphetamines: 20 samples confirmed. 19 contained 
MDMA. Three samples contained amphetamine. 
Benzodiazepines; 18 samples confirmed. Of these, 
eight did not contain any benzodiazepine tested for by 
the State Laboratory Further investigations into other 
possible benzodiazepines are being carried out. 
Diazepam occurred most frequently, present in nine of 
the positive samples. 
Cannabinoids: Confirmatory analysis was carried out 
on 16 samples. The three that were found to be negative 
gave a screening result close to the kit cut-off of 10 
ng/ml. 
Cocaine: Only tour samples screened positive for 
cocaine. The two samples that screened near the kit cut-
off were confirmed to be negative. Cocaine was 
confirmed to be present in the remaining two samples. 
 
Opiates: GC/MS analysis was carried out on eight 
samples. Two contained 6-monoacetylmorphinc, the 
main heroin metabolite. Codeine only was present in 
one sample, which is present in over-the-counter 
painkillers. 
Methadone: Confirmed present in all nine samples 
analysed for methadone. 
Conclusions 
The results presented here indicate that there has been a 
significant increase in driving under the influence of 
drugs in Irish roads since 1987, when 14.6 per cent of 
samples (under the legal alcohol limit) tested were 
found positive for drugs. This preliminary study has 
found that the percentage has risen to approximately 37 
per cent. 
 The extensive survey being carried out in 
2000/2001 will identify true trends in the types of drugs 
being taken, their combination with alcohol, and the 
extent of polydrug use. 
 This work also highlights the importance- of 
confirmatory analysis in the interpretation of drug 
screening results. 
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